Patent cliff risk appears manageable
The host argued the patent cliff risk for GLP-1 drugs seems manageable due to patent thickets, manufacturing complexity, and patient preference for premium performance.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.